Guggenheim Reiterates Buy on Endo Int'l (ENDP) Following Updated Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/3/2026
- Wall St futures gain on Mideast deal hopes; healthcare in focus
- Fed's Williams says rate hikes possible if inflation persists
- Citi says buy these 3 chip stocks on pullback
- Microsoft joins, Broadcom exits Goldman's top-stocks list
- Deutsche Bank raises S&P 500 earnings estimates on the back of the solid Q2 beats
- Morgan Stanley Downgrades Circle Internet Group (CRCL) to Underweight
- Myanmar's detained former leader Aung San Suu Kyi meets Red Cross official
- Supernus and Indivior agree to all-stock merger of equals
- Curium to acquire Lantheus in deal valued at up to $8 billion
- Bernstein raises server shipment forecast as AI infrastructure spending grows
- After-Hours Stock Movers: AAPL, AMZN, COIN, RBLX, RDDT, AXTI, FND, WU, GDDY
- After-Hours Stock Movers: META, MSFT, CMG, SBUX, CVNA, LRCX, FTNT, QCOM, TDOC
- After-Hours Stock Movers: F, BE, STX, WDC, KLAC, SWKS, NXPI, CSGP, ENPH
- After-Hours Stock Movers: FFIV, CDNS, APLD, RMBS, ESI, SANM
- After-Hours Stock Movers: INTC, AMD, ARM, MXL, EW, DECK
RBC Capital Cuts Price Target on Endo Int'l (ENDP) Following Guidance Update
September 29, 2015 7:42 AM EDTRBC Capital maintained a Top Pick rating on Endo International plc (NASDAQ: ENDP), and cut the price target to $100.00 (from $107.00), following a guidance update. ENDP pointed to a 3Q range of $720-740 million in revenue which is 4% below consensus at the midpoint.
Analyst... More
ACETO Corp (ACET) Unit to Acquire Three ANDAs from Endo (ENDP)
September 28, 2015 8:04 AM EDTACETO Corp (NASDAQ: ACET) announced that Rising Pharmaceuticals, Inc., its generic finished dosage form subsidiary, has reached agreement to purchase three ANDAs from a subsidiary of Endo International plc (Nasdaq: ENDP) for the products Methimazole Tablets, Glycopyrrolate Tablets and... More
Endo Int'l (ENDP) Closes Par Pharma Acquisition; Updates Guidance
September 28, 2015 6:34 AM EDTEndo Int'l (NASDAQ: ENDP) announced it has completed its previously announced $8.05 billion acquisition of Par Pharmaceutical Holdings, Inc. from leading global private investment firm TPG.
Through this acquisition, Endo has further established its position as a leading global specialty pharmaceutical company with a fast growing generics business that is among the top five as measured by U.S. sales according to IMS. The acquisition also helps position Endo for long-term double-digit organic growth, enhanced cash flow generation and increased financial flexibility. Endo's generics portfolio now includes an extensive range of in market and... More
